Browse by ORCID

HABRA, K., PEARSON, J.R.D., LE VU, P., PUIG‐SAENZ, C., CRIPPS, M.J., KHAN, M.A., TURNER, M.D., SALE, C. and MCARDLE, S.E.B., 2023. Anticancer actions of carnosine in cellular models of prostate cancer. Journal of Cellular and Molecular Medicine. ISSN 1582-1838

ATOBATELE, A.G., TONOLI, E., VADAKEKOLATHU, J., SAVOCA, M.P., BARR, M., KATARIA, Y., ROSSANESE, M., BURHAN, I., MCARDLE, S., CACCAMO, D. and VERDERIO, E.A.M., 2023. Canonical and truncated transglutaminase-2 regulate mucin-1 expression and androgen independency in prostate cancer cell lines. Cell Death and Disease, 14 (5): 317. ISSN 2041-4889

HABRA, K., MORRIS, R.H., MCARDLE, S.E.B. and CAVE, G.W.V., 2022. Controlled release of carnosine from poly(lactic-co-glycolic acid) beads using nanomechanical magnetic trigger towards the treatment of glioblastoma. Nanoscale Advances. ISSN 2516-0230

LE VU, P., VADAKEKOLATHU, J., IDRI, S., NICHOLLS, H., CAVAIGNAC, M., REEDER, S., KHAN, M.A., CHRISTENSEN, D., POCKLEY, A.G. and MCARDLE, S.E., 2022. A mutated prostatic acid phosphatase (PAP) peptide-based vaccine induces PAP-specific CD8+ T cells with ex vivo cytotoxic capacities in HHDII/DR1 transgenic mice. Cancers, 14 (8): 1970. ISSN 2072-6694

COSMA, G., MCARDLE, S.E., FOULDS, G.A., HOOD, S.P., REEDER, S., JOHNSON, C., KHAN, M.A. and POCKLEY, A.G., 2021. Prostate cancer: early detection and assessing clinical risk using deep machine learning of high dimensional peripheral blood flow cytometric phenotyping data. Frontiers in Immunology, 12: 786828. ISSN 1664-3224

MCARDLE, S.E.B., PAWELEC, G., POCKLEY, A.G. and JOHANSEN, P., 2021. Editorial: Frontiers’ research topic “cancer vaccines: time to think differently!”. Frontiers in Immunology, 12: 771319. ISSN 1664-3224

HABRA, K., MCARDLE, S.E.B., MORRIS, R.H. and CAVE, G.W.V., 2021. Synthesis and functionalisation of superparamagnetic nano-rods towards the treatment of glioblastoma brain tumours. Nanomaterials, 11 (9): 2157. ISSN 2079-4991

ALMSHAYAKHCHI, R., NAGARAJAN, D., VADAKEKOLATHU, J., GUINN, B.-A., REEDER, S., BRENTVILLE, V., METHERINGHAM, R., POCKLEY, A.G., DURRANT, L. and MCARDLE, S., 2021. A novel HAGE/WT1-ImmunoBody® vaccine combination enhances anti-tumour responses when compared to either vaccine alone. Frontiers in Oncology, 11: 636977.

NAGARAJAN, D., PEARSON, J., BRENTVILLE, V., METHERINGHAM, R., POCKLEY, A.G., DURRANT, L. and MCARDLE, S.E., 2021. ImmunoBody®‐HAGE derived vaccine induces immunity to HAGE and delays the growth and metastasis of HAGE‐expressing tumours in vivo. Immunology and Cell Biology. ISSN 0818-9641

POCKLEY, G., SHACKELTON, E., ALI, H., STEPHANIE, M. and KHAN, M., 2021. Novel combinatorial approaches to tackle the immunosuppressive microenvironment of prostate cancer. Cancers, 13 (5): 1145.

CUZZUBBO, S., MANGSBO, S., NAGARAJAN, D., HABRA, K., POCKLEY, A.G. and MCARDLE, S.E.B., 2021. Cancer vaccines: adjuvant potency, importance of age, lifestyle, and treatments. Frontiers in Immunology, 11: 615240. ISSN 1664-3224

PEARSON, J.R.D., CUZZUBBO, S., MCARTHUR, S., DURRANT, L.G., ADHIKAREE, J., TINSLEY, C.J., POCKLEY, A.G. and MCARDLE, S.E.B., 2020. Immune escape in glioblastoma multiforme and the adaptation of immunotherapies for treatment. Frontiers in Immunology, 11: 582106.

HOOD, S.P., COSMA, G., FOULDS, G.A., JOHNSON, C., REEDER, S., MCARDLE, S.E., KHAN, M.A. and POCKLEY, A.G., 2020. Identifying prostate cancer and its clinical risk in asymptomatic men using machine learning of high dimensional peripheral blood flow cytometric natural killer cell subset phenotyping data. eLife, 9: e50936.

ALVES, R., MCARDLE, S.E.B., VADAKEKOLATHU NARAYANAN, J., GONÇALVES, A.C., FREITAS-TAVARES, P., PEREIRA, A., ALMEIDA, A.M., SARMENTO-RIBEIRO, A.B. and RUTELLA, S., 2020. Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α. Journal of Translational Medicine, 18: 2. ISSN 1479-5876

HOOD, S.P., FOULDS, G.A., IMRIE, H., REEDER, S., MCARDLE, S.E.B., KHAN, M. and POCKLEY, A.G., 2019. Phenotype and function of activated natural killer cells from patients with prostate cancer: patient-dependent responses to priming and IL-2 activation. Frontiers in Immunology, 9: 3169. ISSN 1664-3224

DOUSH, Y., SURANI, A.A., NAVARRO-CORCUERA, A., MCARDLE, S., BILLETT, E.E. and MONTIEL-DUARTE, C., 2019. SP1 and RARα regulate AGAP2 expression in cancer. Scientific Reports, 9: 390. ISSN 2045-2322

FOULDS, G.A., VADAKEKOLATHU, J., ABDEL-FATAH, T.M.A., NAGARAJAN, D., REEDER, S., JOHNSON, C., HOOD, S., MOSELEY, P.M., CHAN, S.Y.T., POCKLEY, A.G., RUTELLA, S. and MCARDLE, S.E.B., 2018. Immune-phenotyping and transcriptomic profiling of peripheral blood mononuclear cells from patients with breast cancer: identification of a 3 gene signature which predicts relapse of triple negative breast cancer. Frontiers in Immunology, 9: 2028. ISSN 1664-3224

COSMA, G., MCARDLE, S.E., REEDER, S., FOULDS, G.A., HOOD, S., KHAN, M. and POCKLEY, A.G., 2017. Identifying the presence of prostate cancer in individuals with PSA levels <20 ng ml−1 using computational data extraction analysis of high dimensional peripheral blood flow cytometric phenotyping data. Frontiers in Immunology, 8, p. 1771. ISSN 1664-3224

LINLEY, A., MATHIEU, M., MCARDLE, S., LU, C. and REES, R., 2017. Breast cancer assay. PCT/GB2013/050794.

ABDEL-FATAH, T.M.A., MCARDLE, S.E., AGARWAL, D., MOSELEY, P.M., GREEN, A.R., BALL, G.R., POCKLEY, A.G., ELLIS, I.O., REES, R.C. and CHAN, S.Y.T., 2016. HAGE in triple negative breast cancer (TNBC) is a novel prognostic, predictive and actionable biomarker: a transcriptomic and protein expression analysis. Clinical Cancer Research, 22 (4), pp. 905-914. ISSN 1078-0432

ABDEL-FATAH, T.M.A., MCARDLE, S.E.B., JOHNSON, C., MOSELEY, P.M., BALL, G.R., POCKLEY, A.G., ELLIS, I.O., REES, R.C. and CHAN, S.Y.T., 2014. HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer. British Journal of Cancer, 110 (10), pp. 2450-2461. ISSN 1532-1827

VADAKEKOLATHU, J., MILES, A.K., BOOCOCK, D.J. and MCARDLE, S.E.B., 2014. Identification of tumor antigens for clinical evaluation. In: Tumor immunology and immunotherapy. Oxford: Oxford University Press, pp. 127-129. ISBN 9780199676866

SAIF, J.M.S., VADAKEKOLATHU, J., RANE, S.S., MCDONALD, D., AHMAD, M., MATHIEU, M., POCKLEY, A.G., DURRANT, L., METHERINGHAM, R., REES, R.C. and MCARDLE, S.E.B., 2014. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice. European Journal of Immunology, 44 (4), pp. 994-1004. ISSN 0014-2980

MCARDLE, S.E.B., POCKLEY, A.G., GIBSON, G.R. and REES, R.C., 2014. Prostate cancer: important steps and considerations in the design of therapeutic vaccines. OncoImmunology, 3 (3). ISSN 2162-402X

PHATAK, V.M., CROFT, S.M., RAMESHAIAH SETTY, S.G., SCARPELLINI, A., HUGHES, D.C., REES, R., MCARDLE, S. and VERDERIO, E.A.M., 2013. Expression of transglutaminase-2 isoforms in normal human tissues and cancer cell lines: dysregulation of alternative splicing in cancer. Amino Acids, 44 (1), pp. 33-44. ISSN 0939-4451

LAVERSIN, S.A.-S., PHATAK, V.M., POWE, D.G., LI, G., MILES, A.K., HUGHES, D.C., BALL, G.R., ELLIS, I.O., GRITZAPIS, A.D., MISSITZIS, I., MCARDLE, S.E.B. and REES, R.C., 2013. Identification of novel breast cancer-associated transcripts by uniGene database mining and gene expression analysis in normal and malignant cells. Genes, Chromosomes and Cancer, 52 (3), pp. 316-329. ISSN 1098-2264

LINLEY, A.J., MATHIEU, M.G., MILES, A.K., REES, R.C., MCARDLE, S.E.B. and REGAD, T., 2012. The helicase HAGE expressed by malignant melanoma-initiating cells is required for tunor cell proliferation in vivo. Journal of Biological Chemistry, 287 (17), pp. 13633-13643.

MATHIEU, M.G., LINLEY, A.J., REEDER, S.P., BADOUAL, C., TARTOUR, E., REES, R.C. and MCARDLE, S.E.B., 2010. HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers. Cancer Immunity, 10, p. 2.

ALI, S.A., REZVAN, H., MCARDLE, S.E., KHODADADI, A., ASTEAL, F.A. and REES, R.C., 2009. CTL responses to Leishmania mexicana gp63-cDNA vaccine in a murine model. Parasite Immunology, 31 (7), pp. 373-383.

ZHANG, W., CASPELL, R., KARULIN, A.Y., AHMAD, M., HAICHEUR, N., ABDELSALAM, A., JOHANNESEN, K., VIGNARD, V., DUDZIK, P., GEORGAKOPOULOU, K., MIHAYLOVA, A., SILINA, K., APTSIAURI, N., ADAMS, V., LEHMANN, P.V. and MCARDLE, S., 2009. ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring -- even in hands of ELISPOT-inexperienced investigators. Journal of Immunotoxicology, 6 (4), pp. 227-234. ISSN 1547-691X

KAPOOR, K.N., BARRY, D.T., REES, R.C., DODI, I.A., MCARDLE, S.E.B., CREASER, C.S. and BONNER, P.L.R., 2009. Estimation of peptide concentration by a modified bicinchoninic acid assay. Analytical Biochemistry, 393 (1), pp. 138-140.

LINLEY, A.J., MILES, A.K., AL-FAWAZ, M., LU, C., MCARDLE, S.E.B., REES, R.C. and MATHIEU, M.G., 2009. Non-X-linked cancer/testis antigens: identification, expression profile and immunogenicity [review]. Current Trends in Immunology.

MCARDLE, S.E. and REES, R.C., 2009. Tumor immunlogy: new perspectives [review]. Cancer Research, 15 (18), pp. 7157-7159.

RILEY, C.L., MATHIEU, M.G., CLARK, R.E., MCARDLE, S.E. and REES, R.C., 2009. Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable? Cancer Immunology Immunotherapy, 58 (9), pp. 1489-1499.

MCARDLE, S.E., 2008. Cancer vaccines: uses of HLA transgenic mice compared to genetically modified mice. Frontiers in Bioscience, 14 (12), pp. 4640-4651.

WALTON, T.J., LI, G., SETH, R., MCARDLE, S.E., BISHOP, M.C. and REES, R.C., 2008. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. DNA demethylation and histone deacetylation inhibition act synergistically to re-express oestrogen receptor beta and induce apoptosis in prostate cancer cell-lines [working title], 68 (2), pp. 210-222.

LI, G., ASSUDANI, D.P., LINE, A., CAO, A., MILES, A., REES, R.C. and MCARDLE, S.E.B., 2008. Identification of metastasis associated antigen 1 (MTA1) by serological screening of prostate cancer cDNA libraries. Open Biochemistry Journal, 2, pp. 100-107.

MILES, A.K., ROGERS, A., PARKINSON, R., REES, R.C. and MCARDLE, S.E., 2008. Overview of prostate biomarkers as potential targets for immunotherapy [review]. Current Cancer Therapy Reviews, 4 (2), pp. 86-95.

ASSUDANI, D.P., LI, G., LINE, A., FUMING, C., MILES, A.K., REES, R.C. and MCARDLE, S.E., 2008. SEREX analysis of prostate cancer cDNA libraries: identification of metastasis associated antigen (MTA1) [in press]. Open Biochemistry Journal.

ASSUDANI, D.P., MCARDLE, S.E., AHMAD, M., LI, G., REES, R.C. and ALI, S.A., 2008. Vaccination strategies for malignant diseases. In: Treatment of cancer. Hodder Arnold, p. 167.

MATHIEU, M.G., KNIGHTS, A.J., PAWELEC, G., RILEY, C.L., WERNET, D., LEMONNIER, F.A., STRATEN, P.T., MUELLER, L., REES, R.C. and MCARDLE, S.E., 2007. HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides. Cancer Immunology Immunotherapy, 56 (12), pp. 1885-1895. ISSN 0340-7004

MILES, A.K., ROGERS, A., LI, G., SETH, R., POWE, D., MCARDLE, S.E., MCCULLOCH, T.A., BISHOP, M.C. and REES, R.C., 2007. Identification of a novel prostate cancer-associated tumor antigen. Prostate, 67 (3), pp. 274-287. ISSN 0270-4137

HORTON, R.B.V., LAVERSIN, S.A.S., REEDER, S.P., REES, R.C. and MCARDLE, S.E., 2007. Identification of immunogenic MHC class II tyrosinase-derived peptides using HLA-DR1 and HLA-DR4 transgenic mice. Protein and Peptide Letters, 14 (5), pp. 455-460. ISSN 0929-8665

LI, G., ASSUDANI, D.P., MCARDLE, S.E.B. and REES, R.C., 2007. SEREX analysis of prostate cancer cDNA libraries: the identification of MTA1 as a wide-spread tumour associate protein. Cancer Immunology Immunotherapy, 56 (1), pp. 70-80.

ASSUDANI, D.P., HORTON, R.B.V., MATHIEU, M.G., MCARDLE, S.E. and REES, R.C., 2007. The role of CD4(+) T cell help in cancer immunity and the formulation of novel cancer vaccines. Cancer Immunology Immunotherapy, 56 (1), pp. 70-80. ISSN 0340-7004

MUELLER, L., MCARDLE, S.E., DERHOVANESSIAN, E., FLAD, T., KNIGHTS, A.J., REES, R.C. and PAWELEC, G., 2005. Current strategies for the identification of immunogenic epitopes of tumor antigens. In: M.L. DISIS, ed., Immunotherapy of Cancer. Humana Press.

LI, G., ALI, S.A., MCARDLE, S.E., MIAN, S., AHMAD, M., MILES, A. and REES, R.C., 2005. Immunity to tumour antigens. Current Pharmaceutical Design, 11 (27), pp. 3501-3509. ISSN 1381-6128

ROJAS, J.M., MCARDLE, S.E.B., HORTON, R.B.V., BELL, M., MIAN, S., LI, G., ALI, S.A. and REES, R.C., 2005. Peptide immunisation of HLA-DR-transgenic mice permits the identification of a novel HLA-DRbeta 1*0101-and HLA-DRbeta 1*0401-restricted epitope from p53. Cancer Immunology Immunotherapy, 54 (3), pp. 243-253. ISSN 0340-7004

AHMAD, M., REES, R.C., MCARDLE, S.E., LI, G., MIAN, S., ENTWISLE, C., LOUDON, P. and ALI, S.A., 2005. Regulation of CTL responses to MHC-restricted class I peptide of the gp70 tumour antigen by splenic parenchymal CD4(+) T cells in mice failing immunotherapy with DISC-mGM-CSF. International Journal of Cancer, 115 (6), pp. 951-959. ISSN 0020-7136

ALI, S.A., AHMAD, M., LYNAM, J., MCLEAN, C.S., ENTWISLE, C., LOUDON, P., CHOOLUN, E., MCARDLE, S.E., LI, G., MIAN, S. and REES, R.C., 2004. Anti-tumour therapeutic efficacy of OX40L in murine tumour model. Vaccine, 22 (2728), pp. 3585-3594. ISSN 0264-410X

KNIGHTS, A.J., MCARDLE, S.E., MÜLLER, L., MCCULLOCH, T.A., REES, R.C. and PAWELEC, G., 2004. Identification of a novel epitope derived from the cancer-germline antigen, HAGE, displaying both in-vitro and in-vivo immunogenicity. Cancer Cell International, 41 (350). ISSN 1475-2867

PARKINSON, R.J., MIAN, S., BISHOP, M.C., GRAY, T., LI, G., MCARDLE, S.E., ALI, S. and REES, R.C., 2003. Disabled infectious single cycle herpes simplex virus (DISC-HSV) is a candidate vector system for gene delivery/expression of GM-CSF in human prostate cancer therapy. Prostate, 56 (1), pp. 65-73. ISSN 0270-4137

MCARDLE, S.E., ALI, S.A., LI, G., MIAN, S. and REES, R.C., 2003. Phenotypic and functional differences of dendritic cells generated under different in vitro conditions. Methods in Molecular Medicine, 81, pp. 359-375.

MIAN, S., BALL, G., HORNBUCKLE, J., HOLDING, F., CARMICHAEL, J., ELLIS, I., ALI, S., LI, G., MCARDLE, S.E., CREASER, C. and REES, R., 2003. A prototype methodology combining surface-enhanced laser desorption/ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin under in v. Proteomics, 3 (9), pp. 1725-1737.

REES, R.C., MCARDLE, S.E., MIAN, S., LI, G., AHMAD, M., PARKINSON, R. and ALI, S.A., 2002. Disabled infectious single cycle-herpes simplex virus (DISC-HSV) as a vector for immunogene therapy of cancer. Current Opinion in Molecular Therapeutics, 4 (1), pp. 49-53. ISSN 1464-8431

ALI, S.A., LYNAM, J., MCLEAN, C.S., ENTWISLE, C., LOUDON, P., ROJAS, J.M., MCARDLE, S.E., LI, G., MIAN, S. and REES, R.C., 2002. Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity. Journal of Immunology, 168 (7), pp. 3512-3519. ISSN 0022-1767

MCARDLE, S.E., REES, R.C., MULCAHY, K.A., SABA, J., MCINTYRE, C.A. and MURRAY, A.K., 2000. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant. Cancer Immunology Immunotherapy, 49 (8), pp. 417-425. ISSN 0340-7004

MCARDLE, S.E., REES, R.C., MULCAHY, K.A., SABA, J., MCINTYRE, C.A. and MURRAY, A.K., 2000. p53 conformational mutants are killed preferentially by cytotoxic T lymphocytes generated in vitro using dendritic cells pulsed with new wild-type p53 peptide. Cancer Immunology Immunotherapy, 49 (8).